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Stratifying Patients With Stroke in Trials That Target
Brain Repair
Steven C. Cramer, MD
Abstract—A number of therapies are emerging that have the potential to reduce poststroke disability by promoting repair.
Careful evaluation of patients with stroke might help distinguish those who are most likely to respond to a restorative
therapy from those who lack biological substrate needed to achieve gains. Potential approaches to such stratification are
considered, including measures of brain injury or of poststroke brain function. (Stroke. 2010;41[suppl 1]:S114-S116.)
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An acute stroke initiates a number of events. Chief amongthese is brain injury, including the ischemic cascade,
penumbra and its evolution, delayed neuronal loss, and apopto-
sis. However, a stroke also sets into motion a series of events
related to repair. Within the first few days of an infarct, the brain
initiates a number of processes related to restoration of function,
such as increased expression of growth-associated genes, ele-
vated levels of growth factors, angiogenesis, greater endogenous
neural stem cell proliferation and migration, and increased
dendritic arborization and synaptogenesis.1,2
These events represent biological targets for a class of
therapies that fall under the rubric of brain repair. Although
most patients show some degree of spontaneous behavioral
improvement in the weeks-months after a stroke, this recov-
ery is generally incomplete, and as a result stroke remains a
major cause of human disability.3 Brain repair therapies
introduced during the days-weeks after stroke onset do not
target neuroprotection; rather, such therapies aim to amplify
innate repair mechanisms and thereby further improve behav-
ioral outcomes after stroke. A growing literature also docu-
ments the ability of such interventions to improve behavioral
status when introduced in the chronic phase, months-years
after stroke, likely on the backbone of similar repair-based
mechanisms.
A number of therapeutic classes are under investigation to
promote brain repair after stroke.4 The list includes growth
factors, other large molecules such as monoclonal antibodies,
stem cells, physiotherapy-based interventions, robotic de-
vices, electromagnetic stimulation, neuroprosthetics, and
small molecules. Small molecule approaches are wide-
ranging and include drugs that modulate level of activity
within specific neurotransmitter systems, vitamins, phospho-
diesterase type 5 inhibitors, selective serotonin reuptake
inhibitors, and more. The preclinical literature is blossoming
with such studies, and many have been examined in human
trials, including phase III trials in some cases.5,6
Stratifying Stroke Patients to Optimize
Prescription of Repair Therapies
Heterogeneity remains a major challenge for stroke research.7
Currently, approved therapies for treating stroke are generally
focused on the artery or the blood clot. Repair-based therapies
that target neural tissue might, therefore, benefit from means
to classify likely from nonlikely treatment responders.
A key question is, therefore, how to optimally prescribe such
repair-based therapies. Although poststroke repair trials to date
have mainly relied on behavioral measures as key entry crite-
ria,5,6,8,9 patient selection might benefit from incorporation of
measures that characterize the biological target, and do so in a
manner that increases the likelihood of treatment effectiveness.
There are many levels with which this approach is currently
taken in broader medical practice. For example, treatment
decisions in myocardial disease are sometimes made by incor-
porating a measure of cardiac injury and viability.10 Function of
bronchiolar, adrenal, and other organs is probed to stratify
patients and thereby define treatment. Specific measures of the
biological target are sometimes used to direct treatment choices,
such as when measuring breast cancer HER-2/neu antigen levels
to decide on usage of trastuzumab or not.11
Details apart from patient selection can be learned. Thus,
the amount, timing, or duration of therapy might also be
informed by some measure of the targeted biological system.
For example, in hypothyroidism, treatment is based on
measures of serum TSH over weeks, rather than of hypothy-
roid symptoms over months.
How might these principles be applied to trials of repair-
based therapies? A first step is to define valid, reliable
measures of the biological system—measures that can be
considered for use in stratifying patients with stroke. Such
measures might consider brain systems in relation to injury,
viability, function, or level of specific biological target, as
these specific measures have proven fruitful elsewhere in
medicine for optimizing treatment effects.
Received July 7, 2010; accepted July 16, 2010.
From the University of California, Irvine, Calif.
Correspondence to Steven C. Cramer, MD, University of California Irvine Medical Center, 101 The City Drive South, Building 53 Room 203, Orange,
CA 92868-4280. E-mail scramer@uci.edu
© 2010 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.110.595165
S114
Key clues regarding the best stratifying variables post-
stroke come from studies of the natural history of stroke
recovery in humans, such as can be found in measures of
behavior, injury, or brain function. Candidate stratifying
variables are listed below.
Behavior
From a behavioral perspective, most patients show some spon-
taneous recovery after a stroke. Although spontaneous recovery
generally evolves through characteristic stages, it can vary
widely across neurological modalities12 and across subjects.
Nonetheless, measures exist that have good predictive value.13
Individual variables such as medication use and social factors
(eg, education or support systems) might also be important
influences on degree of recovery.
Injury
Many features of brain injury influence outcome after stroke.
A perennial predictor is the total volume of injury. Location
of injury is important, for example, injury to specific brain
systems at times being more informative for clinical insight.
For example, hand motor function after stroke is better
explained by degree of injury to the hand motor map on motor
cortex than by total volume of injury.14 Injury can be defined
using many different measures, including anatomic MRI,
diffusion tensor imaging, neurophysiology, metabolic fea-
tures, or spectroscopy.
Function
A single stroke changes the function of multiple brain areas.
Studies of this functional reorganization have found good
concordance across multiple methods including functional
MRI (fMRI), positron emission tomography, electroencepha-
lography, magnetoencephalography, and transcranial mag-
netic stimulation. Thus, when primary cortical areas, or their
key white matter tracts, are injured, their function is reduced
and behavior declines. At the same time, compensatory brain
events arise that appear to help maximize behavioral status,
though clearly incompletely so. Multiple nodes in a distrib-
uted network increase activity toward driving behavior, and
shifts arise in interhemispheric balance. Such patterns of
functional reorganization of brain networks have been con-
firmed in multiple brain systems, including motor, sensory,
language, and attention. In some cases, the structural coun-
terpart to these reorganizational changes have been measured
in parallel, such as the thickness of primary sensory cortex15
or the size of residual corticospinal tract.16
The Table lists some specific candidate measures for
stratifying patients based on the above approach. Each of
these measures has been found to have value for distinguish-
ing stroke subpopulations in relation to poststroke recovery.
Many more measures can likely be added.
The goal is to use a stratifying measure that is derived from
a biological model of the therapeutic intervention, and that is
useful to distinguish patients across the model. A measure
that has reliable predictive or stratifying value would be
optimal; one whose measurements are sensibly related to a
biological model generates maximum confidence. In this
regard, note that several of the MRI techniques, such as fMRI
and diffusion tensor imaging, and neurophysiological meth-
ods, such as transcranial magnetic stimulation, that are used
to study human subjects have been directly applied to study
animal models of stroke and its repair-based therapies.
Studies that use the same methods to extract identical metrics
across species are needed to clarify these biological models.
Examples of Patient Stratification in Repair-Based
Stroke Studies
Several examples have been published whereby bedside and
functional neuroimaging measures have predictive value for
treatment effects. In patients with chronic stroke, a smaller
degree of ipsilesional primary motor cortex activation during an
fMRI scan obtained at study baseline predicted gains from
motor-related therapy, and did so more strongly than many other
clinical or imaging metrics did.17 Furthermore, patients who
showed the highest gains from therapy also showed the largest
boosts in motor cortex activation. The model suggests that
patients who have intact but underused motor cortex resource
can be trained to increase motor cortex activity, and that fMRI at
baseline is providing a useful measure of the therapy’s biological
target. Stinear et al18 achieved good success at predicting arm
motor gains from therapy using diffusion tensor imaging–based
measures of white matter integrity, transcranial magnetic stim-
ulation (TMS)-based measures of motor system function, demo-
graphics, and behavioral status. The model suggests that therapy
gains rely on an intact corticospinal tract, and that diffusion
Table. Candidates for Stratifying Patients in Repair-Based Trials
Demographics and medical history
Age















Tractography (eg, from diffusion tensor imaging)16
Anatomic imaging15
Neurophysiology
Motor evoked potentials (eg, from transcranial magnetic stimulation)30
Electroencephalography31
Genetics
Single nucleotide polymorphisms (eg, BDNFval66met)32
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tensor imaging and TMS at baseline provided a useful measure
of this tract. This latter study emphasizes that multivariate
approaches might have greater power than bivariate.
An approach in general medicine that might be instructive to
stratification in repair trials is to use serial assessments before/
after a challenge rather than simply obtaining a single cross-
sectional assessment. Thus, whether assessing function of the
myocardium, bronchioles, or adrenal glands, serial measure-
ments before/after a challenge is often more informative than a
singular basal measurement. Two studies suggest that this might
be true in a repair-based trial, as a repeat fMRI measure midway
through,19 and a repeat TMS measure early into,20 therapy can
significantly distinguish those who will from those who will not
respond well to subsequent intervention.
Future Directions
Several preclinical, and some initial clinical, studies indicate the
potential to improve outcome and reduce disability after stroke
using approaches that focus on repair. Such therapies might have
maximum effect if targeted toward the right patient subpopula-
tions. Thus, once the best repair-based therapies are identified,
major questions remain. For example, which are the subpopu-
lations that are most likely to respond?; and by which means
should such subpopulations be identified? A wide range of
candidate tests exists for such patient stratification (Table).
Initial studies17–20 suggest the potential use of this approach,
though these require independent verification and validation.
Further study of the many factors that influence stroke recovery,
both spontaneous and treatment-induced, will provide a means
to best stratify patients seeking therapies that target brain repair.
The issue of patient stratification might prove to be pivotal in
maximizing effects of repair-based therapies.
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